Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
HIG | <0.01% | $30.82B | +29.39% | 1.83% |
VERX | 0.01% | $8.13B | +121.58% | 0.00% |
GRAL | -0.02% | $595.74M | +4.29% | 0.00% |
NXTC | -0.03% | $22.38M | -31.12% | 0.00% |
EME | -0.04% | $21.48B | +113.28% | 0.20% |
APP | 0.11% | $106.88B | +663.56% | 0.00% |
SRRK | -0.15% | $3.79B | +147.95% | 0.00% |
LQDA | -0.17% | $1.03B | -2.01% | 0.00% |
CVM | 0.20% | $31.46M | -83.52% | 0.00% |
NWL | -0.34% | $4.06B | +14.96% | 2.91% |
FRO | -0.43% | $3.84B | -22.18% | 10.89% |
ALAR | 0.43% | $73.43M | -3.72% | 0.00% |
HWM | -0.44% | $45.76B | +102.81% | 0.23% |
BNED | 0.45% | $300.33M | -91.58% | 0.00% |
MAGN | -0.46% | $650.28M | +4.84% | 0.00% |
WM | -0.47% | $83.18B | +14.25% | 1.45% |
PRT | 0.50% | $46.59M | -17.46% | 10.91% |
GL | -0.53% | $9.44B | -6.47% | 0.86% |
IMNN | 0.60% | $13.05M | +35.12% | 0.00% |
DMLP | 0.60% | $1.60B | +6.19% | 10.26% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
IPGP | 43.80% | $3.12B | -27.44% | 0.00% |
RITM | 42.44% | $5.56B | +0.38% | 9.43% |
NLY | 42.26% | $10.17B | -7.64% | 14.39% |
SRI | 42.01% | $148.69M | -70.00% | 0.00% |
TFX | 41.84% | $8.11B | -29.92% | 0.78% |
VC | 41.77% | $2.28B | -27.69% | 0.00% |
GT | 41.64% | $2.52B | -32.88% | 0.00% |
JOE | 40.69% | $2.55B | -22.64% | 1.19% |
SXT | 40.49% | $2.85B | +7.18% | 2.48% |
DX | 40.12% | $970.67M | -4.45% | 13.15% |
MTX | 39.92% | $2.29B | +7.44% | 0.58% |
VSH | 39.70% | $2.22B | -27.00% | 2.47% |
CNS | 39.61% | $4.34B | +25.81% | 2.79% |
IVR | 39.15% | $467.62M | -16.03% | 21.11% |
CCS | 39.13% | $2.17B | -19.98% | 1.52% |
BN | 39.10% | $82.83B | +40.15% | 0.59% |
WRLD | 38.96% | $630.38M | -13.95% | 0.00% |
YORW | 38.76% | $438.70M | -17.25% | 2.80% |
PKST | 38.47% | $383.83M | -35.40% | 8.61% |
ARW | 38.39% | $5.89B | -3.07% | 0.00% |
Current Value
$148.921 Year Return
Current Value
$148.921 Year Return
Finnhub
LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration optionTOKYO and CAMBRIDGE, Mass., Jan. 13,...
Finnhub
LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration optionTOKYO and CAMBRIDGE, Mass., Jan. 13,...
SeekingAlpha
Anavex's promising Alzheimer's drug, Blarcamesine, could provide hope with its potential to slow cognitive decline, pending EMA approval. Read more here.
Finnhub
Drugmaker Biogen will buy all outstanding shares of Sage Therapeutics that it does not already own for $7.22 apiece, a filing showed on Friday, sending the latter's stock up 34% in extended trade. ...
Yahoo
(Bloomberg) -- Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025.Most Read from BloombergWhat Robotaxis Brought San FranciscoNYC Condo Owners May Bear Costs of Landmark Green Building LawNYC’s Subway Violence Deters Drive to Bring Workers Back to OfficeAmbitious High-Speed Rail Plans Advance in the Baltic RegionDutch Central Bank Restores Amsterdam’s ‘Ugliest Building’Companies including Biogen I
SeekingAlpha
NervGen is engaged in groundbreaking research in spinal cord injury treatment. Read here for an update on the research's potential impact on NGENF's stock value.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
KNSL | -17.75% | $9.70B | +8.81% | 0.15% |
HUSA | -17.59% | $21.99M | -1.18% | 0.00% |
TCTM | -12.47% | $6.23M | -37.75% | 0.00% |
CME | -10.35% | $82.59B | +16.03% | 4.54% |
PULM | -10.29% | $21.95M | +206.95% | 0.00% |
AON | -9.69% | $75.59B | +16.41% | 0.76% |
EVRI | -9.68% | $1.17B | +28.46% | 0.00% |
PGR | -9.48% | $138.02B | +39.50% | 2.50% |
STG | -9.42% | $28.83M | -36.52% | 0.00% |
KSPI | -6.90% | $17.41B | -5.63% | 4.04% |
MMM | -6.76% | $71.45B | +45.15% | 2.77% |
CPSH | -6.58% | $25.56M | -23.48% | 0.00% |
VHC | -6.48% | $28.01M | +19.97% | 0.00% |
BTCT | -6.32% | $20.70M | -28.47% | 0.00% |
ALL | -5.77% | $47.93B | +19.84% | 2.06% |
ERIE | -5.71% | $18.13B | +14.00% | 1.35% |
K | -5.68% | $28.10B | +47.08% | 2.77% |
TXMD | -5.62% | $12.69M | -51.75% | 0.00% |
TRVG | -5.26% | $51.84M | -3.35% | 0.00% |
WRB | -4.92% | $21.61B | +19.78% | 0.69% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
USDU | -28.56% | $381.18M | 0.5% |
VIXY | -25.83% | $195.31M | 0.85% |
UUP | -24.52% | $607.07M | 0.77% |
CTA | -18.62% | $497.20M | 0.76% |
EQLS | -17.68% | $9.16M | 1% |
TAIL | -11.37% | $65.56M | 0.59% |
BILZ | -10.52% | $614.54M | 0.14% |
TBLL | -9.05% | $2.00B | 0.08% |
AGZD | -7.59% | $142.77M | 0.23% |
TBIL | -6.71% | $4.78B | 0.15% |
DBE | -6.16% | $48.12M | 0.77% |
BOXX | -5.44% | $4.68B | 0.1949% |
SGOV | -5.00% | $30.83B | 0.09% |
DBO | -4.66% | $214.31M | 0.77% |
DBA | -4.61% | $790.77M | 0.93% |
UNG | -4.50% | $790.37M | 1.06% |
KCCA | -2.71% | $116.13M | 0.87% |
XBIL | -1.77% | $641.82M | 0.15% |
GSG | -1.06% | $1.02B | 0.75% |
CORN | -0.77% | $63.58M | 0.2% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IBB | 54.55% | $6.45B | 0.45% |
BBH | 54.17% | $399.16M | 0.35% |
FBT | 52.79% | $1.14B | 0.56% |
FXH | 50.71% | $1.07B | 0.62% |
RSPH | 50.49% | $834.11M | 0.4% |
PBE | 49.05% | $254.47M | 0.58% |
XBI | 48.01% | $6.43B | 0.35% |
XHE | 47.08% | $220.80M | 0.35% |
MOAT | 46.61% | $15.11B | 0.46% |
FHLC | 46.18% | $2.68B | 0.084% |
VHT | 45.62% | $16.71B | 0.1% |
GNOM | 45.52% | $71.69M | 0.5% |
IXJ | 45.05% | $3.70B | 0.41% |
RDIV | 44.10% | $801.31M | 0.39% |
XPH | 43.98% | $158.66M | 0.35% |
PID | 43.89% | $821.56M | 0.53% |
ARKG | 43.80% | $1.14B | 0.75% |
MORT | 43.35% | $287.46M | 0.43% |
XLV | 42.84% | $37.73B | 0.09% |
IYH | 42.81% | $3.13B | 0.39% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
KMLM | -0.06% | $337.46M | 0.9% |
COMT | 0.26% | $688.84M | 0.48% |
SHV | 0.35% | $19.10B | 0.15% |
HIGH | 0.39% | $281.53M | 0.52% |
XHLF | 0.53% | $939.87M | 0.03% |
GBIL | 0.64% | $5.82B | 0.12% |
CORN | -0.77% | $63.58M | 0.2% |
GSG | -1.06% | $1.02B | 0.75% |
MINT | 1.12% | $12.00B | 0.35% |
USCI | 1.58% | $193.45M | 1.07% |
XBIL | -1.77% | $641.82M | 0.15% |
KCCA | -2.71% | $116.13M | 0.87% |
CLSE | 2.78% | $243.97M | 1.55% |
PDBC | 2.86% | $4.15B | 0.59% |
TPMN | 3.31% | $41.63M | 0.65% |
FBY | 3.44% | $165.62M | 0.99% |
MEAR | 3.68% | $772.54M | 0.25% |
CSHI | 4.19% | $508.09M | 0.38% |
DBC | 4.41% | $1.30B | 0.87% |
UNG | -4.50% | $790.37M | 1.06% |